- Home
- QSI vs PLRX Comparison
QSI vs PLRX Comparison
Compare QSI & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- PLRX
- Stock Information
- Founded
- QSI 2013
- PLRX 2015
- Country
- QSI United States
- PLRX United States
- Employees
- QSI N/A
- PLRX N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- PLRX Health Care
- Exchange
- QSI Nasdaq
- PLRX Nasdaq
- Market Cap
- QSI 633.2M
- PLRX 641.5M
- IPO Year
- QSI N/A
- PLRX 2020
- Fundamental
- Price
- QSI $2.24
- PLRX $11.21
- Analyst Decision
- QSI Buy
- PLRX Strong Buy
- Analyst Count
- QSI 2
- PLRX 7
- Target Price
- QSI $3.25
- PLRX $40.50
- AVG Volume (30 Days)
- QSI 60.2M
- PLRX 560.2K
- Earning Date
- QSI 02-27-2025
- PLRX 02-26-2025
- Dividend Yield
- QSI N/A
- PLRX N/A
- EPS Growth
- QSI N/A
- PLRX N/A
- EPS
- QSI N/A
- PLRX N/A
- Revenue
- QSI $2,266,000.00
- PLRX N/A
- Revenue This Year
- QSI $193.90
- PLRX N/A
- Revenue Next Year
- QSI $173.18
- PLRX N/A
- P/E Ratio
- QSI N/A
- PLRX N/A
- Revenue Growth
- QSI 232.26
- PLRX N/A
- 52 Week Low
- QSI $0.61
- PLRX $10.22
- 52 Week High
- QSI $5.77
- PLRX $18.92
- Technical
- Relative Strength Index (RSI)
- QSI 49.02
- PLRX 37.19
- Support Level
- QSI $1.85
- PLRX $11.02
- Resistance Level
- QSI $2.68
- PLRX $12.70
- Average True Range (ATR)
- QSI 0.83
- PLRX 0.80
- MACD
- QSI -0.15
- PLRX -0.18
- Stochastic Oscillator
- QSI 9.95
- PLRX 8.21
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.